I've highlighted PAVM as a potential biomed play with good upside potential in this forum. Now I am introducing BCRX. They develop and produce novel 'orphan' drugs for rare but serious diseases. Recently, they achieved FDA and Japanese approval for Ordaleyo (EU coming soon). Factor D research is underway with phase two trials happening at the moment.

PAVM is a speculative and risky play but BCRX is more so. Despite this, with Ordaleyo sales coming online, I think that BCRX is around 50-60% undervalued. If the Factor D research comes through then who knows, BCRX could be worth $100 p share.